Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

No, the 505b2 pathway only applies to safety, as far as I know. Someone else may know better than I. The advantage comes from mouse studies in parallel with human performance, so far. That is, efficacy in mice was dose dependent. We will know soon enough if that increased efficacy continues beyond 200 mg. All evidence points in that direction and that safety should extend beyond 600 mg.